Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical development of bromodomain and extra‐terminal (BET) protein inhibitors differs from the traditional course of drug development. These drugs are simultaneously being evaluated for treating a wide spectrum of human diseases due to their novel mechanism of action. BET proteins are epigenetic “readers,” which play a primary role in transcription. Here, we briefly describe the BET family of proteins, of which BRD4 has been studied most extensively. We discuss BRD4 activity at latent enhancers as an example of BET protein function. We examine BRD4 redistribution and enhancer reprogramming in embryonic development, cancer, cardiovascular, autoimmune, and metabolic diseases, presenting hallmark studies that highlight BET proteins as attractive targets for therapeutic intervention. We review the currently available approaches to targeting BET proteins, methods of selectively targeting individual bromodomains, and review studies that compare the effects of selective BET inhibition to those of pan‐BET inhibition. Lastly, we examine the current clinical landscape of BET inhibitor development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 8×
“There is now a considerable amount of data, generated by various groups, demonstrating differential outcomes of pan‐ versus selective BD inhibition.16,38,45,157,210 In one investigational study, gene expression in hepatocellular carcinoma cell line (HepG2 cells) following treatment with the pan‐BETi JQ1 was contrasted…”
BackgroundResultInfluentialSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 13×
“This developmental differentiation process involves a coordinated program requiring abundant expression of a well‐defined, but limited panel of genes, including lineage‐determining genes octamer‐binding transcription factor 4 (OCT4), sex determining region Y‐box transcription factor 2 (SOX2) and homeobox protein NANOG…”
BackgroundInfluentialSelective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 4×
“Mediator aid in chromatin remodeling and the aggregation of transcriptional machinery, and BRD4's CTM binding with PTEF‐b releases RNA Pol II pausing, advancing the elongation of oncogene transcripts.(76) These SEs form in proximity to well‐known oncogenes like the MYC proto‐oncogene (MYC), Immunoglobulin Lambda Like…”
BackgroundInfluentialCoactivator condensation at super-enhancers links phase separation and gene control
Sabari, B. R., Dall’Agnese, A., Boija, A., Klein, I. A., Coffey, E. L., Shrinivas, K., Abraham, B. J., Hannett, N. M., Zamudio, A. V., Manteiga, J. C., et al. (2018) · Science · doi:10.1126/science.aar3958 · Cited by 2,595
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly
Nakayama, J.-I., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. S. (2001) · Science · doi:10.1126/science.1060118 · Cited by 1,739
Structure and ligand of a histone acetyltransferase bromodomain
Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., Zhou, M.-M., & Zhou, M.-M. (1999) · Nature · doi:10.1038/20974 · Cited by 1,732
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
The selection and function of cell type-specific enhancers
Heinz, S., Romanoski, C. E., Benner, C., & Glass, C. K. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3949 · Cited by 1,010 · cited 1×
“This response mechanism is the cells' intrinsic ability to alter chromatin structure and form new enhancers in proximity to response genes.(75,120,125) This “cellular plasticity” affords terminally differentiated cells the”
BackgroundLatent Enhancers Activated by Stimulation in Differentiated Cells
Ostuni, R., Piccolo, V., Barozzi, I., Polletti, S., Termanini, A., Bonifacio, S., Curina, A., Prosperini, E., Ghisletti, S., & Natoli, G. (2013) · Cell · doi:10.1016/j.cell.2012.12.018 · Cited by 867 · cited 6×
“In mouse bone marrow–derived macrophages, Ostuni et al. found that upon stimulation with lipopolysaccharide (LPS) and various other noxious stimuli, genomic regions that were unmarked in basal conditions acquired these marks, and thus were termed latent enhancers.”
BackgroundResultInfluentialNF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.024 · Cited by 614 · cited 16×
“cells in atherosclerosis, inflammatory signaling in cardiomyocytes is upregulated through activation of the master transcription factor NF‐κB in HF.(56) Additionally, transforming growth factor beta (TGF‐β) signaling is increased”
BackgroundResultInfluentialSelective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Faivre, E. J., McDaniel, K. F., Albert, D. H., Mantena, S. R., Plotnik, J. P., Wilcox, D., Zhang, L., Bui, M. H., Sheppard, G. S., Wang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-1930-8 · Cited by 408 · cited 1×
“There is now a considerable amount of data, generated by various groups, demonstrating differential outcomes of pan‐ versus selective BD inhibition.(16,38,45,157,210) In one investigational study, gene expression in hepatocellular carcinoma cell line (HepG2 cells) following treatment with the pan‐BETi JQ1 was contrast…”
BackgroundBET Bromodomains Mediate Transcriptional Pause Release in Heart Failure
Anand, P., Brown, J. D., Lin, C. Y., Qi, J., Zhang, R., Artero, P. C., Alaiti, M. A., Bullard, J., Alazem, K., Margulies, K. B., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.013 · Cited by 406 · cited 6×
“coactivator of pathologic gene transactivation in these models.(53) Mirroring what occurs in vascular endothelial”
BackgroundResultInfluentialHouzelstein, D., Bullock, S. L., Lynch, D. E., Grigorieva, E. F., Wilson, V. A., & Beddington, R. S. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3794-3802.2002 · Cited by 318 · cited 1×
“also apparent in homozygous BRD4 knockout mice, where BRD4 knockout is embryonically lethal before implantation.(101) BRD4, and likely other BET proteins, interact with histone acetyltransferases, deacetylases, and other chromatin remodelers.”
BackgroundDuan, Q., McMahon, S., Anand, P., Shah, H., Thomas, S., Salunga, H. T., Huang, Y., Zhang, R., Sahadevan, A., Lemieux, M. E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5084 · Cited by 262 · cited 4×
“In metabolic, inflammatory, and cardiovascular diseases, transcriptional reprogramming also occurs through similar underlying processes.(4,14,53,56,75) When the cellular environment of”
BackgroundResultInfluentialClinical trials for BET inhibitors run ahead of the science
Andrieu, G., Belkina, A. C., & Denis, G. V. (2016) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2016.06.004 · Cited by 247
Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery
Greer, C. B., Tanaka, Y., Kim, Y. J., Xie, P., Zhang, M. Q., Park, I.-H., & Kim, T. H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.013 · Cited by 174
Double bromodomain‐containing gene Brd2 is essential for embryonic development in mouse
Shang, E., Wang, X., Wen, D., Greenberg, D. A., & Wolgemuth, D. J. (2009) · Developmental Dynamics · doi:10.1002/dvdy.21911 · Cited by 156 · cited 2×
“BRD2 modulates gene transcription in connection with cell cycle activity of proliferating cells in embryonic development, neural development, and in cancers/tumors at later stages of development.(83,84) During embryogenesis, Brd2‐deficient mice exhibit delayed fibroblast proliferation, neural tube closure defects, and…”
BackgroundClick chemistry enables preclinical evaluation of targeted epigenetic therapies
Tyler, D. S., Vappiani, J., Cañeque, T., Lam, E. Y. N., Ward, A., Gilan, O., Chan, Y.-C., Hienzsch, A., Rutkowska, A., Werner, T., et al. (2017) · Science · doi:10.1126/science.aal2066 · Cited by 146 · cited 5×
“These and other studies confirm that pan‐BETi lead to vast effects on gene expression and activity while BD2‐ selective binding often has less extensive effects.(45,157,210) They also suggest that the benefits of BD2‐selective BETi may be more specific than pan‐BETi in inhibiting those transcriptional changes associat…”
BackgroundResultInfluentialZhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138 · cited 5×
“There is now a considerable amount of data, generated by various groups, demonstrating differential outcomes of pan‐ versus selective BD inhibition.16,38,45,157,210 In one investigational study, gene expression in hepatocellular carcinoma cell line (HepG2 cells) following treatment with the pan‐BETi JQ1 was contrasted…”
BackgroundInfluentialEfferocytosis in atherosclerotic lesions: Malfunctioning regulatory pathways and control mechanisms
Tajbakhsh, A., Rezaee, M., Kovanen, P. T., & Sahebkar, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.003 · Cited by 134
Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival
Segatto, M., Fittipaldi, R., Pin, F., Sartori, R., Dae Ko, K., Zare, H., Fenizia, C., Zanchettin, G., Pierobon, E. S., Hatakeyama, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01645-7 · Cited by 101
DeMars, K. M., Yang, C., Castro-Rivera, C. I., & Candelario-Jalil, E. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.096 · Cited by 66
Identification of Covalent Bromodomain Binders through DNA Display of Small Molecules
Daguer, J., Zambaldo, C., Abegg, D., Barluenga, S., Tallant, C., Müller, S., Adibekian, A., & Winssinger, N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412276 · Cited by 65 · cited 6×
“There is now a considerable amount of data, generated by various groups, demonstrating differential outcomes of pan‐ versus selective BD inhibition.16,38,45,157,210 In one investigational study, gene expression in hepatocellular carcinoma cell line (HepG2 cells) following treatment with the pan‐BETi JQ1 was contrasted…”
BackgroundInfluentialJiang, F., Wei, Q., Li, H., Li, H., Cui, Y., Ma, Y., Chen, H., Cao, P., Lu, T., & Chen, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115181 · Cited by 48
Cited by
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development
Chen, J., Tang, P., Wang, Y., Wang, J., Yang, C., Li, Y., Yang, G., Wu, F., Zhang, J., & Ouyang, L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01835 · Cited by 62
Liu, C., Rioja, I., Bakr, A., Veldwijk, M. R., Sperk, E., Herskind, C., Weichenhan, D., Prinjha, R. K., Plass, C., Schmezer, P., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33989 · Cited by 17
Fu, R., Zu, S.-J., Liu, Y.-J., Li, J.-C., Dang, W.-Z., Liao, L.-P., Liu, L.-P., Chen, P.-Y., Huang, H.-M., Wu, K.-H., et al. (2022) · Bioengineered · doi:10.1080/21655979.2022.2066756 · Cited by 12
Metadata
- Authors
- Kulikowski, E., Rakai, B. D., & Wong, N. C. W.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2020-09-14
- Volume
- 41
- Issue
- 1
- Pages
- 223-245
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3087130502
- Cited by
- 102
- References
- 27
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.